Literature DB >> 29732469

The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29732469     DOI： 10.1007/s00417-018-4004-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Long-term Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration in a Clinical Setting.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-12-23       Impact factor: 5.258

2.  High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-08       Impact factor: 3.117

3.  Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-11-11       Impact factor: 5.258

4.  Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-26       Impact factor: 3.117

5.  Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-06       Impact factor: 3.117

6.  The fate of eyes with wet AMD beyond four years of anti-VEGF therapy.

Authors:  Justus G Garweg; Johanna J Zirpel; Christin Gerhardt; Isabel B Pfister
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-03       Impact factor: 3.117

7.  INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Prospective Pilot Study.

Authors:  Anita Barikian; Haytham Salti; Ammar Safar; Ziyad R Mahfoud; Ziad F Bashshur
Journal:  Retina       Date:  2017-07       Impact factor: 4.256

8.  LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors:  Ilkay Kilic Muftuoglu; Mostafa Alam; Qi Sheng You; Raouf Gaber; Hema L Ramkumar; Nadia Mendoza; Amit Meshi; William R Freeman
Journal:  Retina       Date:  2018-03       Impact factor: 4.256

9.  Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.

Authors:  Glenn J Jaffe; Peter K Kaiser; Desmond Thompson; Andrea Gibson; Namrata Saroj; Robert Vitti; Alyson J Berliner; Jeffrey S Heier
Journal:  Ophthalmology       Date:  2016-06-28       Impact factor: 12.079

10.  Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis).

Authors:  Sandeep Grover; Ravi K Murthy; Vikram S Brar; Kakarla V Chalam
Journal:  Am J Ophthalmol       Date:  2009-05-09       Impact factor: 5.258
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.